01.19.21

Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)

Source: Bausch + Lomb

01.07.21

Kala Pharmaceuticals Announces Commercial Availability of Eysuvis for the Treatment of Dry Eye Disease

Source: Kala Pharmaceuticals

01.07.21

SIFI Launches Dry Eye Disease Device Synfo

Source: SIFI

12.18.20

Oyster Point Submits NDA to FDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Source: Oyster Point Pharma

12.15.20

Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Disease

Source: Palatin Technologies

12.08.20

Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease

Source: Aldeyra Therapeutics

12.08.20

Novaliq Announces First Patient Randomized in the ESSENCE-2 Phase 3 Trial of Dry Eye Treatment CyclASol

Source: Novaliq

11.24.20

Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027

Source: Grand View Research, Inc.

11.24.20

Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGD

Source: Bausch Health Companies Inc.

11.03.20

Aurinia Pharmaceuticals’ Dry Eye Drug Candidate Does Not Meet Primary Endpoint

Source: Aurinia Pharmaceuticals

View more stories